Krebs Biochemicals & Industries Share Price

Krebs Biochem

CMP as on 07-May-21 15:50

₹ 125.00
3.30 2.71%

Open

₹ 122.85

Turnover (lac)

₹ 29

Prev. Close

₹ 121.70

Day's Vol (shares)

₹ 22,806

Day's Range (₹)

₹ 121.00
₹ 129.40

CMP as on07-May-21 15:39

₹ 126.20
4.2 3.44%

Open

₹ 124.35

Turnover (lac)

Prev. Close

₹ 122.00

Day's Vol (shares)

₹ 2,137

Day's Range

₹ 121.50
₹ 126.90

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 06-Apr-2021 - -
Pursuant to the exercise of further conversion option by Ipca Laboratories Ltd. and upon receipt of the balance application money, the Board of directors of the Company at their meeting held today i.e on 6th April, 2021 have converted 19,40,000 warrants and allotted 19,40,000 (Nineteen Lakhs Forty Thousand ) Equity shares of Rs.10/- each of the Company at a price of Rs. 86/- per Equity Share, including premium of Rs. 76/- per share to M/s Ipca Laboratories Limited, the entity forming part of the promoter group. The Equity shares now allotted on conversion of warrants issued shall rank pari passu with the existing equity shares of the Company in all respects. The paid up equity capital of the company with the aforesaid allotment has increased from 19620586 equity of Rs. 10/- each to 21560586 Equity shares of Rs.10/- each aggregating to Rs.21,56,05,860/-
Board Meeting - 23-Jan-2021 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2021 ,inter alia, to consider and approve we herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Saturday, 30th January, 2021 to transact, inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 31st December 2020. 2. Any other matter with the permission of the Chair. Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 29th December 2020 and shall re-open 48 hours after the declaration of results we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 30th January, 2021: (a) The unadited financial results for the quarter and Nine months ended 31st December, 2020 along with the Auditors Limited Review Report thereon (Enclosed herewith) have been adopted by the Board. (As per BSE Announcement Dated on 30/01/2021)
Board Meeting - 29-Oct-2020 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2020 ,inter alia, to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 5th November, 2020 to transact, inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter and half year ended 30th September 2020. 2. Any other matter with the permission of the Chair. Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 1st October 2020 and shall re-open 48 hours after the declaration of results. we herewith submit to the Exchange the quick result for the quarter and Half Year ended 30th September, 2020 as approved by the Board of Directors at their meeting held on 5th November, 2020. we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 5th November ,2020 : (a) The unaudited financial results for the quarter and Half Year ended 30th September, 2020 along with the Auditors Limited Review Report thereon (Enclosed herewith) have been adopted by the Board. (AS Per BSE Announcement Dated on 05.11.2020) we wish to inform that the Board of Directors at its meeting held on 5th November ,2020 have considered and approved Re-Appointment of Mr. Raj Kamal Prasad Verma as Independent Director for a further Period of 5years (Second Term) with effect from 13th February, 2021. (As per BSE Announcement Dated on 09/11/2020)
Board Meeting - 31-Jul-2020 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2020 ,inter alia, to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Friday, 7th August 2020 to transact, inter alia the following: 1. To consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 30th June 2020. 2. To consider and approve Directors Report and the annexures thereto of the 28th Annual General Meeting 3. Any other matter with the permission of the Chair. Further, in connection to the above, trading window for dealing in shares of the Company was closed for the designated persons, connected persons and their relatives as defined in the Code of conduct under SEBI (PIT) Regulations, 2015 as amended, from 1st July 2019 and shall re-open 48 hours after the declaration of results. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI LODR Regulations], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 7th August ,2020 : (a) The Unaudited financial results for the quarter ended 30th June, 2020 along with the Limited review Report thereon (Enclosed herewith) have been adopted by the Board. (b) The Boards Report and annexures has been approved for the 28th Annual General Meeting (As per BSE Announcement Dated on 7/8/2020)
Board Meeting - 11-Jun-2020 - -
KREBS BIOCHEMICALS & INDUSTRIES LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/06/2020 ,inter alia, to consider and approve We herewith intimate the Exchange that the meeting of Board of Directors of the Company is scheduled to be held on Monday, 15th June 2020 to transact, inter alia the following: 1. To consider and approve the Audited financial results along with the Auditors Report for the quarter and year ended 31st March 2020. 2. Any other matter with the permission of the Chair. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [SEBI LODR Regulations], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 15th June ,2020 : (a) The Audited financial results for the quarter and Year ended 31st March, 2020 along with the Auditor Report thereon (Enclosed herewith) have been adopted by the Board. (As Per BSE Announcement dated on 15.06.2020) we herewith intimate the Exchange that the Board of Directors at their meeting held on 15th June, 2020 has considered and approved interalia the following: 1. Appointment of M/s DSM Ram, Proprietor of DSMI & Associates, Company Secretaries having PC No.4239 as Secretarial Auditors of the Company for conducting the secretarial Audit for the financial year 2020-2021. 2. Appointment of Suryanarayana & Suresh, Chartered Accountants having Firm registration No.006631S as Internal Auditors of the Company. (As Per BSE Announcement Dated on 16.06.2020) Pursuant to the submission of financial results and outcome of the Board meeting dated 15th June, 2020 for the quarter and year ended 31st March, 2020 and your email dated 14th July, 2020 stating discrepancy with respect to declaration of unmodified opinion, please find attached the results along with the declaration for your record and review (As Per BSE Announcement Dated on 14.07.2020)
Board Meeting - 20-May-2020 - -
the Company at their meeting held today have allotted 16,20,000 (Sixteen Lakhs Twenty Thousand ) Equity shares of Rs.10/- each of the Company for cash at a price of Rs. 86/- per Equity Share, including premium of Rs. 76/- per share to M/s Ipca Laboratories Limited, the entity forming part of the promoter group
Open ZERO Brokerage Demat Account